For decades, depression has been explained to patients as a “chemical imbalance” in the brain, a vague phrase that never specified which chemicals, in which cells, were going wrong. A study published in May 2026 in Nature Genetics brings that picture into much sharper focus. A research team led by investigators at institutions including those listed in the paper’s author affiliations profiled the molecular machinery inside individual brain cells from people who had major depressive disorder, pinpointing two cell types, excitatory neurons and microglia, that carry abnormal regulatory patterns linked to genetic risk for the condition.
The finding matters because it shifts the search for better treatments away from broad, whole-brain approaches and toward the specific cells and gene-regulatory processes that appear most consistently disrupted.
What the study actually measured
The research team examined postmortem brain tissue from the dorsolateral prefrontal cortex, a region involved in decision-making, working memory, and emotional regulation, all functions that can deteriorate during depressive episodes. Using a technique called single-nucleus ATAC-seq (snATAC-seq), they mapped “chromatin accessibility” in individual cell nuclei. Chromatin is the tightly wound structure of DNA and proteins inside every cell. When stretches of chromatin are open, the genes in those stretches can be switched on more easily; when they are closed, those genes are effectively silenced. Reading these open-or-closed patterns one cell at a time allowed the researchers to identify which cell populations harbor the regulatory changes most closely tied to depression.
The experimental design, documented in a public dataset deposited in the NCBI Gene Expression Omnibus, paired male and female donor nuclei to help control for sex-based biological variation, an important consideration given that depression prevalence and underlying biology differ between men and women. The team then integrated the chromatin data with gene-expression information to identify where depression-associated genetic variants concentrate their effects.
Two cell types stood out
Excitatory neurons, the cells responsible for transmitting activating signals across brain circuits, showed disease-linked regulatory disruptions. That result did not appear in isolation. A separate large-scale transcriptomic analysis published in Nature Communications independently confirmed that excitatory neurons display convergent molecular changes in synaptic pathways across people with major depressive disorder. The fact that two different methods, chromatin profiling and RNA-based gene expression, point to the same cell type strengthens the case that excitatory neuron dysfunction is a reproducible biological signal, not a statistical fluke.
Microglia, the brain’s resident immune cells, also emerged with abnormal regulatory patterns. Research published in Brain, Behavior, and Immunity has shown that microglial function interacts with environmental stressors to shape sex-specific depression risk, suggesting that immune activation inside the brain may help determine how stress translates into mood symptoms. That finding fits within a broader body of evidence linking neuroinflammation to mood disorders. Earlier postmortem studies had documented both neuronal and glial abnormalities in depression, but those investigations lacked the resolution to attribute changes to specific cell populations or connect them to particular genetic variants.
Supporting evidence from animal and patient-derived models
Animal research adds biological plausibility. A peer-reviewed study using detailed neural recordings and circuit manipulations showed that depressive-like states in animals arise from excitation-inhibition imbalances in specific brain circuits, demonstrating that disruptions in distinct neuronal populations can produce depression-relevant behavior.
Patient-derived models tell a parallel story. GABA interneurons grown from cells of people with depression exhibit abnormal neural activity linked to the serotonin receptor HTR2C. Transcriptomic surveys of the human prefrontal cortex have also found that inhibitory neuron subtype markers are altered in mood disorders, including major depression. Together, these lines of evidence reinforce the idea that depression involves coordinated changes across multiple neuronal and glial cell types rather than a defect in any single pathway.
What researchers still cannot answer
The strongest evidence so far comes from postmortem tissue and laboratory models, not from living patients tracked over time. Chromatin accessibility patterns measured after death capture a snapshot, not a timeline. Researchers cannot yet say whether the regulatory disruptions in excitatory neurons and microglia cause depressive symptoms, result from them, or reflect a third factor such as medication history or chronic stress. The study’s donor-pairing strategy controls for some confounders, but publicly available metadata do not detail age distributions, comorbid conditions, or treatment histories, limiting how broadly the results apply.
No clinical trial data yet connect these cell-type findings to symptom severity or treatment response. The gap between identifying a chromatin change in a postmortem neuron and designing a drug that corrects that change in a living brain remains substantial. Functional validation, for instance using techniques that can switch specific cell populations on and off in living human tissue, has not been performed for these particular regulatory variants. And while animal models can demonstrate that excitation-inhibition imbalances produce depression-like behavior, rodent stress responses do not map perfectly onto human mood disorders.
The microglial findings raise their own questions. Microglia influence synaptic pruning, cytokine release, and interactions with other brain support cells called astrocytes, but which of these processes matters most in human depressive episodes is unclear. Sex-specific effects add another layer: the interaction between microglial function and environmental stressors may differ substantially between men and women, and the current dataset does not fully resolve those differences or capture hormonal influences across the lifespan.
There is also the challenge of genetic complexity. Major depressive disorder is highly polygenic, meaning thousands of common genetic variants each contribute a small increment of risk. The Nature Genetics study maps where those variants likely act at the chromatin level, but it does not identify single “depression genes” that could serve as straightforward drug targets. Many of the implicated regions are noncoding, affecting gene regulation rather than protein structure, and the downstream consequences of altering those regulatory elements in specific cell types remain to be worked out.
Why precision matters for future depression therapies
Most widely prescribed antidepressants, including SSRIs, work by altering neurotransmitter levels across the entire brain. That approach helps many patients, but roughly one-third of people with major depression do not respond adequately to existing medications. The new findings suggest one possible reason: current drugs may not be reaching the right cells or the right regulatory processes.
If excitatory neurons and microglia in the prefrontal cortex are where genetic risk for depression converges, then future therapies could, in principle, be designed to act on those populations more precisely. That goal is still distant. No drugs currently in clinical trials specifically target the chromatin-level disruptions identified in this study. But the work provides a biological roadmap that drug developers and neuroscientists previously lacked: a cell-type-specific address for where depression’s genetic roots appear to take hold.
Longitudinal studies in living patients, combining genetics, brain imaging, peripheral biomarkers, and clinical follow-up, will be needed to determine how early these cell-type-specific changes emerge, how they shift with treatment, and whether they can serve as reliable biomarkers. For now, the practical significance is conceptual but important. Depression appears rooted not in a diffuse chemical imbalance but in specific disruptions of neuronal and immune cell function within key cortical circuits, and science is finally developing the tools precise enough to see them.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
